What is Cytomos?
Cytomos specializes in high-throughput cell analysis, providing data-rich insights that significantly accelerate bioprocess development. Through its flagship AuraCyt and Celledonia systems, the firm offers a transformative approach to cell line development and bioprocess optimization. By replacing traditional, labor-intensive methods with rapid, automated analysis, Cytomos empowers biopharmaceutical teams to reduce operational costs and shorten time-to-market for complex therapeutics, including viral vectors and advanced cell therapies. The company operates at the intersection of biotechnology and industrial efficiency, serving a critical need for precision in the rapidly evolving bioprocessing landscape.
How much funding has Cytomos raised?
Cytomos has raised a total of $13.3M across 3 funding rounds:
Angel/Seed
$1.9M
Other Financing Round
$5M
Other Financing Round
$6.3M
Angel/Seed (2022): $2M with participation from Scottish Enterprise and Old College Capital
Other Financing Round (2023): $5M led by Archangels, Old College Capital, British Business Bank, and Scottish Enterprise
Other Financing Round (2024): $6.4M supported by Scottish Enterprise, Archangel Capital Partners, Edinburgh Innovations, and British Business Bank
Key Investors in Cytomos
Scottish Enterprise
A national economic development agency of the Scottish Government that provides strategic support and funding to help businesses scale and enter international markets.
British Business Bank
A government-owned development bank focused on increasing the supply of credit and providing financial advisory services to small and medium-sized enterprises.
Old College Capital
The in-house venture investment fund of the University of Edinburgh, dedicated to supporting high-growth, early-stage businesses associated with the university's research ecosystem.
What's next for Cytomos?
With this latest infusion of capital, Cytomos is well-positioned to scale its commercial operations and deepen its penetration into international markets. The strategic focus will likely center on enhancing the throughput capabilities of its existing hardware while expanding its software suite to provide deeper analytical integration for its clients. As the demand for rapid, reliable cell analysis grows within the monoclonal antibody and cell therapy sectors, Cytomos is poised to leverage its technological edge to become an industry standard. Future milestones will likely involve further collaborative research initiatives and the continued deployment of its systems to support the next generation of biopharmaceutical manufacturing.
See full Cytomos company page
